A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

被引：3
|
作者：
Ott, P. A. [1 ,2 ]
Pavlick, A. C. [3 ]
Johnson, D. B. [4 ]
Hart, L. L. [5 ]
Infante, J. R. [6 ]
Luke, J. J. [7 ]
Lutzky, J. [8 ]
Rothschild, N. [9 ]
Spitler, L. [10 ]
Cowey, C. L. [11 ]
Alizadeh, A. [12 ]
Salama, A. [13 ]
He, Y. [14 ]
Bagley, R. G. [15 ]
Zhang, J. [15 ]
Hamid, O. [16 ]
机构：
[1] Dana Farber Canc Inst, Melanoma Ctr, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA
[3] NYU, Sch Med, Dept Med, New York, NY USA
[4] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA
[5] Florida Canc Specialists, Hematol Oncol, Ft Myers, FL USA
[6] Tennessee Oncol PLLC, Dept Med, Nashville, TN USA
[7] Univ Chicago, Hematol Oncol, Chicago, IL 60637 USA
[8] Mt Sinai Comprehens Canc Ctr, Div Hematol Oncol, Dept Med, Miami Beach, FL USA
[9] Florida Canc Specialists, Dept Med, W Palm Beach, FL USA
[10] St Marys Hosp, Northern Calif Melanoma Ctr, San Francisco, CA USA
[11] Baylor Univ, Med Ctr, Baylor Skin Malignancy & Treatment Ctr, Dallas, TX USA
[12] Georgia Canc Specialists, Cent Res, Decatur, GA USA
[13] Duke Univ, Dept Med, Durham, NC USA
[14] Celldex Therapeut Inc, Biostat, Hampton, NJ USA
[15] Celldex Therapeut Inc, Clin Sci, Hampton, NJ USA
[16] Angeles Clin & Res Inst, Dept Translat Res ImmunoOncol, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw379.42
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1147P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study
    Yardley, D. A.
    Weaver, R.
    Melisko, M. E.
    Saleh, M. N.
    Arena, F. P.
    Forero, A.
    Cigler, T.
    Stopeck, A.
    Citron, D.
    Oliff, I.
    Bechhold, R.
    Loutfi, R.
    Garcia, A.
    Crowley, E.
    Green, J.
    Yellin, M. J.
    Davis, T. A.
    Vandat, L. T.
    CANCER RESEARCH, 2012, 72
  • [22] Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma
    Sznol, M.
    Hamid, O.
    Hwu, P.
    Kluger, H.
    Hawthorne, T.
    Crowley, E.
    Simantov, R.
    Pavlick, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] mTOR pathway inhibition induces GPNMB expression and sensitizes breast cancer cells to an antibody-drug conjugate targeting GPNMB
    Biondini, Marco
    Rose, April
    Annis, Matthew
    Ferrario, Cristiano
    Puertollano, Rosa
    Basik, Mark
    Siegel, Peter
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 46 - 47
  • [24] Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB
    Pollack, Vincent A.
    Alvarez, Enrique
    Tse, Kam Fai
    Torgov, Michael Y.
    Xie, Sam
    Shenoy, Suresh G.
    MacDougall, John R.
    Arrol, Sharon
    Zhong, Haihong
    Gerwien, Robert W.
    Hahne, William F.
    Senter, Peter D.
    Jeffers, Michael E.
    Lichenstein, Henri S.
    LaRochelle, William J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (03) : 423 - 435
  • [25] Elucidating expression patterns of GPNMB and potential anti-tumor effects of the antibody-drug conjugate, glembatumumab vedotin (CDX-011) in human osteosarcoma primary samples and cell lines
    Piperdi, Sajida
    Kuo, Vicky
    Park, Amy
    Roth, Michael
    Gorlick, Richard
    CANCER RESEARCH, 2014, 74 (19)
  • [26] An Antibody-Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of Melanoma
    Asundi, Jyoti
    Reed, Chae
    Arca, Jennifer
    McCutcheon, Krista
    Ferrando, Ronald
    Clark, Suzanna
    Luis, Elizabeth
    Tien, Janet
    Firestein, Ron
    Polakis, Paul
    CLINICAL CANCER RESEARCH, 2011, 17 (05) : 965 - 975
  • [27] Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study
    Abelman, Rachel Occhiogrosso
    Spring, Laura
    Fell, Geoffrey G.
    Ryan, Phoebe
    Vidula, Neelima
    Medford, Arielle J.
    Shin, Jennifer
    Isakoff, Steven J.
    Moy, Beverly
    Ellisen, Leif W.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advance melanoma
    Hamid, O.
    Sznol, M.
    Pavlick, A. C.
    Kluger, H. M.
    Kim, K. B.
    Boasberg, P. D.
    Simantov, R.
    Davis, T. A.
    Crowley, E.
    Hwu, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] THERAPY OF ADVANCED BLADDER CANCER BY TARGETING HYAL2 WITH ANTIBODY-DRUG CONJUGATE: PRECLINICAL STUDY
    O'Malley, Padraic
    Donelan, William
    Hsieh, Meng-Lun
    Li, Shiwu
    Nguyen, Brianna
    Crispen, Paul
    Kusmartsev, Sergei
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1084 - E1084
  • [30] A pH-responsive crosslinker platform for antibody-drug conjugate (ADC) targeting delivery
    Migliorini, Francesca
    Cini, Elena
    Dreassi, Elena
    Finetti, Federica
    Ievoli, Giovanni
    Macri, Giulia
    Petricci, Elena
    Rango, Enrico
    Trabalzini, Lorenza
    Taddei, Maurizio
    CHEMICAL COMMUNICATIONS, 2022, 58 (75) : 10532 - 10535
12345